Ixekizumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Plaque Psoriasis
Conditions
Plaque Psoriasis, Psoriatic Arthritis
Trial Timeline
Jun 27, 2023 → Sep 23, 2024
NCT ID
NCT05855967About Ixekizumab
Ixekizumab is a approved stage product being developed by Eli Lilly for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05855967. Target conditions include Plaque Psoriasis, Psoriatic Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Plaque Psoriasis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05855967 | Approved | Completed |
| NCT04259346 | Phase 1 | Completed |
| NCT03942042 | Approved | Completed |
| NCT03848416 | Phase 1 | Completed |
| NCT03848403 | Phase 1 | Terminated |
| NCT03485976 | Phase 2 | Completed |
| NCT03099538 | Phase 2 | Completed |
| NCT03137160 | Phase 2 | Completed |
| NCT03073213 | Phase 1 | Completed |
| NCT02387801 | Phase 3 | Completed |
Competing Products
20 competing products in Plaque Psoriasis